Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 mars 2026 08h00 HE | Source: Amphista Therapeutics

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three...
23 mars 2026 03h00 HE | Source: Amphista Therapeutics

Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs

Cambridge, UK, 23rd March 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three...
08 févr. 2026 21h43 HE | Source: InnoCare Pharma

InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

ICP-538 is the first VAV1 degrader approved to enter clinical trials in China and the second globally.